On December 5, 2022 Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that it will effect a 1-for-10 reverse stock split of its issued and outstanding common stock (Press release, Checkpoint Therapeutics, DEC 5, 2022, View Source [SID1234624778]). Checkpoint expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on December 6, 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The reverse stock split was approved on November 3, 2022 by Checkpoint’s Board of Directors and stockholders representing approximately 58% of the voting power of Checkpoint’s outstanding capital stock. The reverse stock split is intended to improve the marketability and liquidity of Checkpoint’s common stock and to remain in compliance with Nasdaq’s continued listing requirements.

Checkpoint’s common stock will continue to trade on the Nasdaq Capital Market under the symbol "CKPT" following the reverse stock split, with a new CUSIP number of 162828206. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in Checkpoint’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued in connection with the reverse stock split and stockholders who would otherwise be entitled to a fractional share will receive a proportional cash payment. After the effectiveness of the reverse stock split, the number of outstanding shares of common stock will be reduced from approximately 93 million to approximately 9.3 million.

Checkpoint’s transfer agent, VStock Transfer, LLC, is also acting as the exchange and paying agent for the reverse stock split. VStock Transfer, LLC will provide instructions to stockholders regarding the process for exchanging physical share certificates. Checkpoint does not expect that stockholders holding their shares in book-entry form or through a bank, broker or other nominee need to take any action in connection with the reverse stock split. Beneficial holders are encouraged to contact their bank, broker or other nominee with any procedural questions. Additional information concerning the reverse stock split can be found in Checkpoint’s definitive Information Statement on Schedule 14C filed with the Securities and Exchange Commission on November 14, 2022.

On December 5, 2022 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will present virtually at the JMP Securities Hematology & Oncology Summit on Wednesday, December 7, 2022, at 11:40 a.m. ET (Press release, BioCryst Pharmaceuticals, DEC 5, 2022, View Source [SID1234624777]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to the live audio webcast and replay of the presentation may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

On December 5, 2022 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the compensation committee of BioCryst’s board of directors granted 21 newly-hired employees stock options to purchase an aggregate of 134,600 shares, and restricted stock units (RSUs) covering an aggregate of 67,300 shares, of BioCryst common stock (Press release, BioCryst Pharmaceuticals, DEC 5, 2022, View Source [SID1234624776]). The options and RSUs were granted as of November 30, 2022, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The options have an exercise price of $13.36 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

On December 5, 2022 Bio-Techne Corporation (NASDAQ: TECH) reported the introduction of MitoBrilliant probes (Press release, Bio-Techne, DEC 5, 2022, View Source [SID1234624775]). These novel probes enable the fluorescent labeling and tracking of mitochondria in live and fixed cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Fluorescent probes that enable highly accurate, sensitive, specific and persistent labeling of mitochondria is critical for a range of demanding scientific and biomedical applications, including high-content screening, flow cytometry and super-resolution microscopy. To enhance the capabilities of modern imaging platforms used to conduct these studies, two types of MitoBrilliant probes have been developed targeting specific applications. MitoBrilliant Live probes enable longer-term, dynamic monitoring of the mitochondrial membrane potential in live cells. The fixable probe, MitoBrilliant 646, provides outstanding performance and resolution post-fixation. Additionally, MitoBrilliant 646 can be used to stain pre-fixed cells and tissue, successfully meeting the demand for a ‘universal’ mitochondrial probe that can fit directly into standard protocols for high-content screening and immunofluorescence.

The probes were developed using the Janelia Fluor fluorescent dye technology, licensed to Bio-Techne by the Howard Hughes Medical Institute, Janelia Research Campus. They confer key properties that make the Janelia Fluor dyes so widely used (such as brightness, photostability, suitability for super-resolution microscopy) into our next-generation MitoBrilliant probes.

"We are committed to developing innovative tools to facilitate and accelerate scientific discovery. The next-generation MitoBrilliant dyes represent exactly that, and we are thrilled to bring these differentiated new probes to the life sciences community" said Will Geist, President of Bio-Techne’s Protein Sciences Segment. "These dyes, developed by Tocris Bioscience (a Bio-Techne brand), showcase our outstanding capabilities in synthetic chemistry and unique capabilities in fluorophore design.

On December 5, 2022 Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, reported that the Company’s Compensation Committee granted 2 new employees inducement stock options to purchase an aggregate of 36,220 common shares, at a per share exercise price of $5.10, the closing price of Aurinia’s common stock on December 2, 2022, and an aggregate of 22,120 inducement restricted stock units (RSUs) (Press release, Aurinia Pharmaceuticals, DEC 5, 2022, View Source [SID1234624774]). The inducement stock options and RSUs have a grant date of December 5, 2022. The stock options and RSUs were granted as inducements material to the new employees entering employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The inducement stock options have a ten-year term and vest over three years with one-third of the shares vesting on the twelve month anniversary from the grant date, and the remaining options vesting in twenty-four equal monthly installments thereafter.

The inducement RSUs shall vest in three equal annual installments on the first, second and third anniversary of the grant date.